Right, the Phase 3 MOVe-OUT trial (NCT04575597) was done in outpatients prior to approval, so to say it was never used in outpatients prior to approval is not accurate. Use in hospitalized patients may have been the focus of research with molnupiravir before the MOVe-OUT trial, but that does not prove that molnupiravir should not be used in an outpatient setting.
That's uselessly pedantic. Yes, the approved out patient usage for sar-cov-2 emergency was out patient in testing too. How could it be otherwise?
But it was never used as an out patient drug in prior studies or FDA approvals for other viral infections. I'm starting to think you aren't debating in good faith...
